NeoGenomics, Inc.

NEO Healthcare Diagnostics & Research

NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

16.65 0.60 −3.48%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−24.5×
Dividend yield
—
F-score
4/9
Altman Z
1.79
Beneish M
−2.68
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(6.33%) (11.56%) (12.42%) (12.99%)

+8 more TTM periods

Piotroski F-Score
5 4 4 4
ROA
(3.78%) (6.73%) (7.21%) (7.52%)
ROIC
(4.20%) (6.48%) (7.11%) (7.44%)
Return on Tangible Assets
(14.55%) (26.61%) (28.98%) (30.66%)
Average Days of Receivables
83.55 81.92 79.91 79.93
Free Cash Flow per Share
(0.04) (0.02) (0.15) (0.13)
Free Cash Flow
(5.29) (3.02) (19.71) (17.05)
Other line items

Show all line items

Columns are period end dates